dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· December 29, 2025

OSB GROUP PLC - Transaction in Own Shares

View original at globenewswire.com
OSB GROUP PLC - Transaction in Own Shares OSB GROUP PLC ISIN: GB00BLDRH360 29 December 2025 LEI number: 213800ZBKL9BHSL2K459 OSB GROUP PLC (the “Company”) Transaction in Own Shares The Company announces that on 24 December 2025 it had purchased a total of 89,815 of its ordinary shares of £0.01 each (the "ordinary share…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Following settlement of the purchases and cancellation of the shares, the Company's total number of ordinary shares in issue shall be 355,971,191.

    80% confidence
  • The Company purchased a total of 89,815 ordinary shares on 24 December 2025 on the London Stock Exchange and CBOE BXE through Citigroup Global Markets Limited.

    80% confidence
  • The repurchased ordinary shares will be cancelled.

    80% confidence
  • On CBOE BXE, 50,000 shares were purchased with a highest price of 644.50p, lowest of 639.00p, and VWAP of 642.31p.

    80% confidence
  • The purchases form part of the Company's share buyback programme announced on 13 March 2025.

    80% confidence
  • On the London Stock Exchange, 39,815 shares were purchased with a highest price of 644.00p, lowest of 638.50p, and VWAP of 642.37p.

    80% confidence
  • No ordinary shares are held in treasury, therefore the total number of voting rights in the Company is 355,971,191.

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
OSB GROUP PLC - Transaction in Own Shares: Source | Via News | fr.via.news